KEGG   DRUG: D09939Help
Entry
D09939                      Drug                                   
Name
Olaratumab (USAN/INN)
Formula
C6554H10076N1736O2048S40
Exact mass
147148.6495
Mol weight
147239.1336
Sequence
(Heavy chain) QLQLQESGPG LVKPSETLSL TCTVSGGSIN SSSYYWGWLR
QSPGKGLEWI GSFFYTGSTY YNPSLRSRLT ISVDTSKNQF SLMLSSVTAA DTAVYYCARQ
STYYYGSGNY YGWFDRWDQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK
VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA
PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN
YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
(Disulfide bridge:22-97; 154-210; 271-331; 377-435, Dimer: 236; 239)
(Light chain) EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP
GQAPRLLIYD ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPAFGQ
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ
ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: 23-88; 134-194; H230-L214, Dimer)
  Type
Peptide
Activity
Treatment of solid tumors
Comment
Monoclonal antibody
Target
PDGFRA tyrosine kinase [HSA:5156] [KO:K04363]
  Pathway
hsa04010  MAPK signaling pathway
hsa04020  Calcium signaling pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04510  Focal adhesion
hsa04540  Gap junction
hsa04810  Regulation of actin cytoskeleton  
 
Brite
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  Receptor tyrosine kinase
   RTK class III (PDGF receptor family)
    PDGFRA tyrosine kinase [HSA:5156] [KO:K04363]
     Olaratumab
      D09939  Olaratumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
1024603-93-7
PubChem: 

» Japanese version   » Back
DBGET integrated database retrieval system